KLOW vs GLOW: What the Research Shows

KLOW and GLOW side by side: what they are, how they are regulated and what is still unknown.

Medically reviewed by Juan Pablo Frías, MD · 3 Oct 2026 · DisclosureUpdated 3 Oct 2026

Four-peptide blendNot FDA approved · unstudied blendKLOWUnapproved blend of GHK-Cu, BPC-157, TB-500 and KPV; an FDA Drugs@FDA search for its component GHK-Cu returned no matches, so no approved product was found.^[12]Healing & recovery+1,524% searchesPre-mixed blendThree-peptide blendNot FDA approved · unstudied blendGLOWUnapproved blend of GHK-Cu, BPC-157 and TB-500; an FDA Drugs@FDA search for its component GHK-Cu returned no matches, so no approved product was found.^[12]Healing & recovery+335% searchesPre-mixed blend

Quick verdict

Where the research points

Summary of studies, not a recommendation

Consider KLOW if…

you want the added KPV component, but note its evidence is mouse and cell work only (no human trial found): KPV-treated mice recovered earlier and regained more body weight in DSS colitis.^[13]

Consider GLOW if…

No sourced contrast for this side yet. We add a point here only when it is tied to a study or label.

What they have in common

Klow is prohibited by WADA at all times, in and out of competition (a blend containing BPC-157)^[1]
Glow is prohibited by WADA at all times, in and out of competition (a blend containing BPC-157)^[1]

Both are prohibited in tested sport (WADA). Status labels come from public FDA and WADA records; see the sources below.

Side by side

Spec comparison

Showing 3 of 13 fields where the two differ. Also called, Category, FDA status, PCAC vote, Jul 2026, WADA, Anti-doping detection, Half-life, Evidence strength, Typical study doses, US searches per month are the same or both unknown.

Field	KLOW	GLOW
Class	Four-peptide blend	Three-peptide blend
Also called	—	—
Category	Healing & recovery	Healing & recovery
FDA status	Not FDA approved · unstudied blend	Not FDA approved · unstudied blend
PCAC vote, Jul 2026	Not on the Jul 2026 agenda	Not on the Jul 2026 agenda
WADA	Prohibited by WADA (S0)Contains BPC-157 (named in S0) and TB-500 (S2.3). A blend is prohibited if any component is.	Prohibited by WADA (S0)Contains BPC-157 (named in S0) and TB-500 (S2.3). A blend is prohibited if any component is.
Anti-doping detection	BPC-157: A 2023 method detects BPC-157 and five main metabolites in human urine at very low concentrations.PMID 37959764 BPC-157: A 2017 anti-doping lab method detects BPC 157 in urine; the peptide was stable in urine for at least 4 days.PMID 28035768 TB-500: A horse-racing doping method identified TB-500 and its metabolites in equine urine and plasma after a single dose (animal data, not human).Journal of chromatography. A 2012, PMID 23084823 TB-500: A direct-urine screen includes TB-500 among the peptides it can detect, at 50 to 500 pg/mL.PMID 26578461	BPC-157: A 2023 method detects BPC-157 and five main metabolites in human urine at very low concentrations.PMID 37959764 BPC-157: A 2017 anti-doping lab method detects BPC 157 in urine; the peptide was stable in urine for at least 4 days.PMID 28035768 TB-500: A horse-racing doping method identified TB-500 and its metabolites in equine urine and plasma after a single dose (animal data, not human).Journal of chromatography. A 2012, PMID 23084823 TB-500: A direct-urine screen includes TB-500 among the peptides it can detect, at 50 to 500 pg/mL.PMID 26578461
Half-life	BPC-157: less than 30 minIV and IM (single and repeated) (rat, beagle dog) · Frontiers in pharmacology 2022, PMID 36588717	BPC-157: less than 30 minIV and IM (single and repeated) (rat, beagle dog) · Frontiers in pharmacology 2022, PMID 36588717
Evidence strength	Human RCT evidence, 4 of 4TB-500: Cardiovascular research 2025, PMID 41229390	Human RCT evidence, 4 of 4TB-500: Cardiovascular research 2025, PMID 41229390
Human studies we summarised	14 human (9 randomized or controlled) of 63 summarised, across ingredients	14 human (9 randomized or controlled) of 54 summarised, across ingredients
Typical study doses	TB-500: 0.05 to 25.0 ug/kg single; 0.5, 2.0 and 5.0 ug/kg daily, single dose or once dailyJournal of cellular and molecular medicine 2021, PMID 34346165 TB-500: 0.5 mg/ml gelMicrobial biotechnology 2021, PMID 34318587 TB-500: 0.1%, 6 times dailyCornea 2015, PMID 25826322	TB-500: 0.05 to 25.0 ug/kg single; 0.5, 2.0 and 5.0 ug/kg daily, single dose or once dailyJournal of cellular and molecular medicine 2021, PMID 34346165 TB-500: 0.5 mg/ml gelMicrobial biotechnology 2021, PMID 34318587 TB-500: 0.1%, 6 times dailyCornea 2015, PMID 25826322
Vial sizes sold	80 mg	50 mg, 70 mg
US searches per month	60,500 · +1,524% searches	60,500 · +335% searches

Bracketed values are pending a sourced figure. Legal data reflects the regulatory events in our tracker.

Sources

1World Anti-Doping Code International Standard Prohibited List 2026World Anti-Doping Agency · 2026wada-ama.orgAccessed 2 Oct 2026
2Stable Isotope Labeling-Based Nontargeted Strategy for Characterization of the In Vitro Metabolic Profile of a Novel Doping BPC-157 in Doping Control by UHPLC-HRMS.Molecules (Basel, Switzerland) · 2023PMID 37959764Accessed 2 Oct 2026
3Detection and in vitro metabolism of the confiscated peptides BPC 157 and MGF R23H.Drug testing and analysis · 2017PMID 28035768Accessed 2 Oct 2026
4Doping control analysis of TB-500, a synthetic version of an active region of thymosin β₄, in equine urine and plasma by liquid chromatography-mass spectrometry.Journal of chromatography. A · 2012PMID 23084823Accessed 2 Oct 2026
5Simplifying and expanding the screening for peptides <2 kDa by direct urine injection, liquid chromatography, and ion mobility mass spectrometry.Journal of separation science · 2016PMID 26578461Accessed 2 Oct 2026
6Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157, a potential drug for treating various wounds, in rats and dogs.Frontiers in pharmacology · 2022PMID 36588717Accessed 2 Oct 2026
7Recombinant human thymosin beta 4 improves ischemic cardiac dysfunction in mice and patients with acute ST-segment elevation myocardial infarction after reperfusion.Cardiovascular research · 2025PMID 41229390Accessed 2 Oct 2026
8A first-in-human, randomized, double-blind, single- and multiple-dose, phase I study of recombinant human thymosin β4 in healthy Chinese volunteers.Journal of cellular and molecular medicine · 2021PMID 34346165Accessed 2 Oct 2026
9Recombinant human thymosin beta-4 (rhTβ4) improved scalp condition and microbiome homeostasis in seborrheic dermatitis.Microbial biotechnology · 2021PMID 34318587Accessed 2 Oct 2026
10Thymosin β4 significantly improves signs and symptoms of severe dry eye in a phase 2 randomized trial.Cornea · 2015PMID 25826322Accessed 2 Oct 2026
11PubMed search: (("GHK-Cu"[tiab] OR GHK[tiab] OR "copper tripeptide"[tiab] OR "copper peptide"[tiab] OR "copper peptides"[tiab] OR "glycyl-L-histidyl-L-lysine"[tiab] OR "glycyl-histidyl-lysine"[tiab] OR "Gly-His-Lys"[tiab]) AND ("BPC-157"[tiab] OR BPC157[tiab] OR "body protection compound"[tiab] OR "pentadecapeptide BPC"[tiab]) AND ("TB-500"[tiab] OR TB500[tiab] OR "thymosin beta-4"[tiab] OR "thymosin beta4"[tiab] OR Tbeta4[tiab])) AND (("GHK-Cu"[tiab] OR GHK[tiab] OR "copper tripeptide"[tiab] OR "copper peptide"[tiab] OR "copper peptides"[tiab] OR "glycyl-L-histidyl-L-lysine"[tiab] OR "glycyl-histidyl-lysine"[tiab] OR "Gly-His-Lys"[tiab]) AND ("BPC-157"[tiab] OR BPC157[tiab] OR "body protection compound"[tiab] OR "pentadecapeptide BPC"[tiab]) AND ("TB-500"[tiab] OR TB500[tiab] OR "thymosin beta-4"[tiab] OR "thymosin beta4"[tiab] OR Tbeta4[tiab]) AND (KPV[tiab] OR "Lys-Pro-Val"[tiab] OR "lysine-proline-valine"[tiab]))PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
12Drugs@FDA (openFDA) search: active ingredient "GHK-Cu"U.S. Food and Drug Administration · 2026api.fda.govAccessed 2 Oct 2026
13Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease.Inflammatory bowel diseases · 2008PMID 18092346Accessed 2 Oct 2026

Found an error? Report a correction.